.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Covington
Argus Health
AstraZeneca
Chinese Patent Office
McKinsey
Johnson and Johnson
Julphar
Federal Trade Commission
Deloitte

Generated: September 23, 2017

DrugPatentWatch Database Preview

Taliglucerase alfa - Generic Drug Details

« Back to Dashboard

What are the generic sources for taliglucerase alfa and what is the scope of taliglucerase alfa freedom to operate?

Taliglucerase alfa
is the generic ingredient in one branded drug marketed by Pfizer and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Taliglucerase alfa has seventy-four patent family members in twenty-five countries.

One supplier is listed for this compound.

Summary for Generic Name: taliglucerase alfa

Tradenames:1
Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list1,255
Drug Prices:see low prices
DailyMed Link:taliglucerase alfa at DailyMed

Pharmacology for Ingredient: taliglucerase alfa

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer
ELELYSO
taliglucerase alfa
POWDER;IV (INFUSION)022458-001May 1, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Pfizer
ELELYSO
taliglucerase alfa
POWDER;IV (INFUSION)022458-001May 1, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Pfizer
ELELYSO
taliglucerase alfa
POWDER;IV (INFUSION)022458-001May 1, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Pfizer
ELELYSO
taliglucerase alfa
POWDER;IV (INFUSION)022458-001May 1, 2012RXYesYes► Subscribe► SubscribeYY ► Subscribe
Pfizer
ELELYSO
taliglucerase alfa
POWDER;IV (INFUSION)022458-001May 1, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: taliglucerase alfa

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,391,638 Cell/tissue culturing device and method► Subscribe
9,220,737Plant cell culture expressing human lysosomal proteins and uses thereof► Subscribe
8,449,876Human lysosomal proteins from plant cell culture► Subscribe
7,951,557Human lysosomal proteins from plant cell culture► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: taliglucerase alfa

Country Document Number Estimated Expiration
Cyprus1114893► Subscribe
Russian Federation2009148012► Subscribe
Israel201799► Subscribe
World Intellectual Property Organization (WIPO)9813469► Subscribe
Australia2004234635► Subscribe
European Patent Office1618177► Subscribe
Russian Federation2009143751► Subscribe
European Patent Office2330205► Subscribe
South Africa200908423► Subscribe
China101855232► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Express Scripts
Teva
Medtronic
US Army
UBS
Covington
QuintilesIMS
Fish and Richardson
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot